Two-Step Selection Strategy Improves TIL Manufacturing From Cold Tumors

Tumor-infiltrating lymphocyte therapy has shown clinical promise, but manufacturing reliable TIL products from “cold” tumors remains difficult. Low TIL yield, tumor-unspecific expansion, and exhausted cell phenotypes can limit the potential for therapeutic response, especially in indications such as pancreatic ductal adenocarcinoma, gastrointestinal cancers, and glioblastoma. A two-step selection approach—combining magnetic CD4+/CD8+ T cell enrichment with GMP-like MACSQuant Tyto sorting for CD45, CD4, CD8, and CD137—offers a more refined way to enrich tumor-reactive cells before expansion.

Explore how the workflow increased T cell purity, supported strong expansion, preserved viability, and generated final TIL products with a less exhausted phenotype.